TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Salipro Biotech AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
6,571
|
5,968
|
7,468 |
| Financial expenses |
1
|
1
|
0 |
| Earnings before taxes |
-4,552
|
-4,264
|
-2,406 |
| EBITDA |
-3,828
|
-3,709
|
-1,847 |
| Total assets |
10,796
|
15,620
|
19,625 |
| Current assets |
4,550
|
9,545
|
14,270 |
| Current liabilities |
1,461
|
1,733
|
1,474 |
| Equity capital |
9,335
|
13,887
|
18,151 |
| - share capital |
69
|
69
|
69 |
| Employees (average) |
8
|
9
|
7 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
86.5%
|
88.9%
|
92.5% |
| Turnover per employee |
821
|
663
|
1,067 |
| Profit as a percentage of turnover |
-69.3%
|
-71.4%
|
-32.2% |
| Return on assets (ROA) |
-42.2%
|
-27.3%
|
-12.3% |
| Current ratio |
311.4%
|
550.8%
|
968.1% |
| Return on equity (ROE) |
-48.8%
|
-30.7%
|
-13.3% |
| Change turnover |
603
|
-1,500
|
2,959 |
| Change turnover % |
10%
|
-20%
|
66% |
| Chg. No. of employees |
-1
|
2
|
1 |
| Chg. No. of employees % |
-11%
|
29%
|
17% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.